Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)
Clinical trial NCT03123588 · TERMINATED
Trial details
- NCT number
- NCT03123588
- Sponsor
- Incyte Corporation
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-11-14
- Primary completion
- 2020-08-03
- Enrollment
- 12
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.